EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modified-release hydrocortisone for female fertility in congenital adrenal hyperplasia

Lea Tschaidse iD, Hanna F Nowotny, Matthias K Auer iD, Orsela Dervishi, Amelie Ziefer, Ann-Christin Welp, Sonja Kunz, Martin Bidlingmaier iD, James Hawley, Brian Keevil, Christian J Thaler, Nina Rogenhofer und 2 weitere

The Journal of Clinical Endocrinology & Metabolism · 28.07.2026

DOI: 10.1210/clinem/dgag303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 28.07.2026. Verfasst von Lea Tschaidse und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine IV, University Hospital, LMU Munich, Germany. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Heisenberg Professorship, Eva Luise und Horst Köhler Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Women with classic congenital adrenal hyperplasia (CAH) suffer from reduced fecundity and fertility. This study aimed to assess fertility outcomes following treatment with modified-release hydrocortisone (MRHC), which more closely replicates the physiological circadian cortisol rhythm.

Methods

In this prospective case series, 8 women with classic CAH and either menstrual irregularities or an unfulfilled desire to have children despite conventional glucocorticoid (GC) therapy for a median duration of 4 years, including assisted reproduction, were switched to MRHC. Hormonal parameters, including morning serum progesterone, 17-hydroxyprogesterone (17OHP), androstenedione, testosterone, and daily salivary 17OHP profiles, were assessed before and after the switch. Clinical outcomes included menstrual cycle regularity and pregnancy.

Results

Descriptive analysis of morning serum samples indicate lower median concentrations of progesterone (0.9 vs 2.1 ng/mL [2.9 vs 6.7 nmol/L]), 17OHP (49.0 vs 131.5 ng/dL [1.5 vs 4.0 nmol/L]), androstenedione (76.0 vs 261.0 ng/dL [2.7 vs 9.1 nmol/L]), and testosterone (27.0 vs 63.0 ng/dL [0.9 vs 2.2 nmol/L]) after switching to MRHC with a lower median hydrocortisone dose equivalent (HDE) (30.0 vs 32.5 mg/day). Salivary 17OHP profiles showed a trend toward lower median area under the curve (AUC) (183.9 vs 676.5 pgxt(n)/mL) and lower concentrations across all time points. Regular menstrual cycles were restored in all patients. All 5 women seeking pregnancy conceived within a median of 9.8 months. Two unintended pregnancies occurred. Outcomes included 6 healthy live births and 1 early miscarriage.

Conclusion

Modified-release hydrocortisone improved hormonal control and was associated with restoration of menstrual cyclicity and high rates of spontaneous conception with a lower HDE. Circadian optimization of GC therapy by MRHC may represent a paradigm shift in fertility management in females with CAH.

Schlagwörter

Stichwörter der Autor:innen

21-hydroxylase deficiencyadrenal androgenscircadian rhythmglucocorticoid replacementmenstrual cyclepregnancy

Autor:innen und Institutionen

  • Department of Medicine IV, University Hospital, LMU Munich, Germany.
  • Department of Clinical Biochemistry, Manchester University Foundation NHS Trust, Manchester Academic Health Sciences Centre, Manchester, UK.
  • Division of Gynecological Endocrinology and Reproductive Medicine, Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.
  • University of Sheffield, Sheffield, UK.

ORCID-Profile: Lea Tschaidse, Matthias K Auer, Martin Bidlingmaier, Nicole Reisch

Förderung

  • Deutsche Forschungsgemeinschaft
  • Heisenberg Professorship
  • Eva Luise und Horst Köhler Stiftung
  • Else Kröner-Fresenius-Stiftung
  • IFCAH
  • International Fund Congenital Adrenal Hyperplasia
  • Förderprogramm für Forschung und Lehre

Zitieren

APA

Tschaidse, L., Nowotny, H. F., Auer, M. K., Dervishi, O., Ziefer, A., Welp, A. C., Kunz, S., Bidlingmaier, M., Hawley, J., Keevil, B., Thaler, C. J., Rogenhofer, N., Ross, R. J. M., & Reisch, N. (2026). Modified-release hydrocortisone for female fertility in congenital adrenal hyperplasia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag303

Vancouver

Tschaidse L, Nowotny HF, Auer MK, Dervishi O, Ziefer A, Welp AC, et al. Modified-release hydrocortisone for female fertility in congenital adrenal hyperplasia. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag303

BibTeX
@article{Tschaidse2026,
  author = {Tschaidse, Lea and Nowotny, Hanna F and Auer, Matthias K and Dervishi, Orsela and Ziefer, Amelie and Welp, Ann-Christin and Kunz, Sonja and Bidlingmaier, Martin and Hawley, James and Keevil, Brian and Thaler, Christian J and Rogenhofer, Nina and Ross, Richard J M and Reisch, Nicole},
  title = {Modified-release hydrocortisone for female fertility in congenital adrenal hyperplasia},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag303}
}
Kostenlos starten →